704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797630859187060736 |
|---|---|
| author | Qingfeng Zhu Robert Anders Damian Trujillo Dirk G Brockstedt Michael Chisamore Juraj Adamik Paul D Kassner William Ho Rakesh Kumar Goyal Adam Grant Shoji Ikeda Marvin Au Denise Nagata Eugene Lurie Mohsen Sabouri Ghomi |
| author_facet | Qingfeng Zhu Robert Anders Damian Trujillo Dirk G Brockstedt Michael Chisamore Juraj Adamik Paul D Kassner William Ho Rakesh Kumar Goyal Adam Grant Shoji Ikeda Marvin Au Denise Nagata Eugene Lurie Mohsen Sabouri Ghomi |
| author_sort | Qingfeng Zhu |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:13:55Z |
| format | Article |
| id | doaj.art-e2bf8d74d1f9425eab362253a82843ff |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:13:55Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-e2bf8d74d1f9425eab362253a82843ff2023-11-11T10:30:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.0704704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancerQingfeng Zhu0Robert Anders1Damian Trujillo2Dirk G Brockstedt3Michael Chisamore4Juraj Adamik5Paul D Kassner6William Ho7Rakesh Kumar Goyal8Adam Grant9Shoji Ikeda10Marvin Au11Denise Nagata12Eugene Lurie13Mohsen Sabouri Ghomi143Johns Hopkins University School of Medicine, Baltimore, MD, USA7Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USAAff16 grid.417411.6Aduro Biotech Inc Berkeley CA USA11RAPT Therapeutics, Inc., South San Francisco, CA, USA10Merck and Co., Inc., Rahway, NJ, USA1RAPT Therapeutics, Inc., South San Francisco, CA, USA11RAPT Therapeutics, Inc., South San Francisco, CA, USA11RAPT Therapeutics, Inc., South San Francisco, CA, USA12RAPT Therapeutics, Redwood City, CA, USA1RAPT Therapeutics, Inc., South San Francisco, CA, USA1RAPT Therapeutics, Inc., South San Francisco, CA, USA1RAPT Therapeutics, Inc., South San Francisco, CA, USA1RAPT Therapeutics, Inc., South San Francisco, CA, USA1RAPT Therapeutics, Inc., South San Francisco, CA, USA1RAPT Therapeutics, Inc., South San Francisco, CA, USA |
| spellingShingle | Qingfeng Zhu Robert Anders Damian Trujillo Dirk G Brockstedt Michael Chisamore Juraj Adamik Paul D Kassner William Ho Rakesh Kumar Goyal Adam Grant Shoji Ikeda Marvin Au Denise Nagata Eugene Lurie Mohsen Sabouri Ghomi 704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer Journal for ImmunoTherapy of Cancer |
| title | 704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer |
| title_full | 704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer |
| title_fullStr | 704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer |
| title_full_unstemmed | 704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer |
| title_short | 704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer |
| title_sort | 704 biological activity of flx475 an oral ccr4 antagonist as monotherapy and in combination with pembrolizumab in advanced cancer |
| work_keys_str_mv | AT qingfengzhu 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT robertanders 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT damiantrujillo 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT dirkgbrockstedt 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT michaelchisamore 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT jurajadamik 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT pauldkassner 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT williamho 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT rakeshkumargoyal 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT adamgrant 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT shojiikeda 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT marvinau 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT denisenagata 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT eugenelurie 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer AT mohsensabourighomi 704biologicalactivityofflx475anoralccr4antagonistasmonotherapyandincombinationwithpembrolizumabinadvancedcancer |